Overview
Sermorelin (GRF 1-29 NH2) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It stimulates the pituitary somatotroph cells to produce and release GH in a physiological pulsatile pattern, preserving the natural GH-IGF-1 axis feedback mechanism. It was FDA-approved for pediatric GH deficiency and is widely studied for adult hormone optimization.
Mechanism of action
Sermorelin binds GHRH receptors on anterior pituitary somatotrophs, activating adenylyl cyclase, increasing cAMP, and triggering GH synthesis and release. Unlike direct GH administration, sermorelin preserves the hypothalamic-pituitary feedback loop — GH and IGF-1 still suppress further release, preventing supraphysiological levels. This results in a more natural GH pulse pattern.
Selected literature
- [01]
Sermorelin: a better approach to management of adult-onset GH insufficiency?
Walker R.F. · Clinical Interventions in Aging · 2006
Sermorelin restored physiological GH pulsatility in GH-deficient adults and improved body composition, sleep quality, and energy levels.
- [02]
GHRH analog effects on body composition in aging adults
Corpas E. et al. · Journal of Clinical Endocrinology & Metabolism · 1992
Sermorelin increased GH and IGF-1 levels and improved lean mass in elderly men while maintaining physiological feedback regulation.
- [03]
Effects of growth hormone-releasing hormone on sleep and cognition
Perras B. et al. · Journal of Sleep Research · 1999
GHRH administration enhanced slow-wave sleep and improved declarative memory consolidation in healthy older adults.
The information on this page is summarized from the published research literature and is provided for reference and educational purposes only. It is not medical advice and should not be used to guide treatment decisions. Our peptides are sold for in-vitro research and laboratory use only.